Multiple Myeloma and Related Disorders

  • Robert A. Kyle
Chapter

Abstract

Multiple myeloma is characterized by the neoplastic proliferation of a single clone of plasma cells engaged in the production of a monoclonal immunoglobulin. Proliferation of the plasma cells in the bone marrow produces skeletal destruction that results in bone pain and fractures. The excessive production of the monoclonal protein (M-protein) can lead to renal failure, recurrent bacterial infections, or hyperviscosity syndrome. Anemia and hypercalcemia are other important features.

Keywords

Multiple Myeloma Plasma Cell Extramedullary Plasmacytoma Primary Amyloidosis Plasma Cell Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R, for the Intergroupe Français du Myélome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.PubMedCrossRefGoogle Scholar
  2. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD, for the Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488–493.PubMedCrossRefGoogle Scholar
  3. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337: 898–909.PubMedCrossRefGoogle Scholar
  4. Gahrton G, Tura S, Ljungman P, Bladé J, Brandt L, Cavo M, Facon T, Gratwohl A, Hagenbeek A, Jacobs P, de Laurenzi A, Van Lint M, Michallet M, Nikoskelainen J, Reiffers J, Samson D, Verdonck L, de Witte T, Volin L. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312–1322.PubMedGoogle Scholar
  5. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50: 29–40.PubMedGoogle Scholar
  6. Kyle RA. “Benign” monoclonal gammopathy—after 20 to 35 years of follow-up. Mayo Clin Proc 1993; 68: 26–36.PubMedCrossRefGoogle Scholar
  7. Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987; 62: 719–731.PubMedCrossRefGoogle Scholar
  8. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59.PubMedGoogle Scholar
  9. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202–1207.PubMedCrossRefGoogle Scholar
  10. Waldenström JG. POEMS: a multifactorial syndrome (editorial). Haematologica 1992; 77: 197–203.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Robert A. Kyle

There are no affiliations available

Personalised recommendations